MCL Literature Feed

The dual HCK/BTK inhibitor KIN-8194 preclinically overcomes primary and acquired BTKi resistance in MCL by targeting HCK-mediated growth and adhesion, offering a novel therapeutic strategy.

The R-GEMOX (rituximab, gemcitabine, oxaliplatin) chemotherapy regimen demonstrates efficacy as a salvage option for patients with relapsed/refractory mantle cell lymphoma in a phase I/II study.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.

This review synthesizes current knowledge on MCL genetic markers, advocating for a personalized medicine approach that integrates molecular profiles like TP53 to improve risk stratification and guide therapy.

This preclinical study identifies a novel cyclin D1 degradation pathway via SUMOylation, showing its disruption causes an MCL-like phenotype and that arsenic trioxide can therapeutically enhance this process.

A qualitative study of Japanese MCL patients reveals that convenience, quality of life, and shared decision-making are key treatment preferences, alongside efficacy and safety, guiding personalized care.

In a large real-world cohort, mantle cell lymphoma patients exhibited higher CAR19 expansion than other lymphomas, which directly correlated with increased toxicity and significantly higher steroid requirements.

Profiling T-cell differentiation stages in MCL reveals novel immunotherapeutic targets in specific patient subsets, suggesting a biomarker-driven approach for future immune-based treatments.

The CDK9 inhibitor enitociclib overcomes resistance to both BTK inhibitors and CAR-T therapy, offering a potential new strategy for double-refractory mantle cell lymphoma.

The SOX11/PRDX2 axis is identified as a key regulator of chemoresistance in aggressive MCL by controlling redox homeostasis, offering a potential new therapeutic target.

In a retrospective analysis of 95 MCL cases, specific histopathological patterns of bone marrow involvement were identified as key prognostic indicators, aiding in initial patient risk stratification.

This case series characterizes the immunohistochemical and molecular genetic profile of rare lacrimal gland MCL, providing crucial diagnostic insights for this uncommon extranodal presentation.

An 85-year-old MCL patient on ibrutinib developed a cutaneous EBV+ NK/T-cell lymphoma that resolved spontaneously, highlighting a rare, potentially indolent lymphoproliferative disorder in this treatment setting.

PRMT5 promotes MCL growth via MYC-driven lipid metabolism reprogramming, identifying it as a poor prognostic marker and a novel therapeutic target with preclinical inhibitor activity.

Adding bortezomib to R-HAD chemotherapy for relapsed/refractory MCL significantly improved time to treatment failure (12 vs 2.6 months), providing a valuable option when BTK inhibitors are unavailable.

A rare case of primary adrenal mantle cell lymphoma presenting as a retroperitoneal mass mimicking paraganglioma highlights the critical need for histological diagnosis of atypical adrenal tumors.

The non-covalent BTK inhibitor pirtobrutinib demonstrates efficacy in mantle cell lymphoma patients who have progressed on prior covalent BTKi therapy, overcoming a common resistance mechanism.

A case of primary ocular adnexal MCL demonstrates its potential for rapid systemic progression, emphasizing the need for thorough initial staging and aggressive systemic therapy despite localized presentation.

A steroid-sparing regimen of doxycycline, cetirizine, and valacyclovir successfully managed exaggerated mosquito bite reactions in an indolent MCL patient, offering a novel approach for this rare cutaneous manifestation.

This UK real-world, intention-to-treat analysis of brexu-cel confirms high efficacy in infused patients but reveals a 30% attrition rate before infusion and significant non-relapse mortality from infection.

This case report demonstrates delayed Hepatitis B reactivation with acalabrutinib in relapsed MCL, underscoring the need for viral screening and prophylaxis with second-generation BTK inhibitors.

This retrospective study confirms that progression of disease within 24 months (POD24) after initial therapy is a strong negative prognostic marker for overall survival in MCL patients.

This case report describes a rare presentation of intestinal MCL causing ileocecal intussusception in an adult, highlighting a critical differential diagnosis for this acute abdominal condition requiring pathological confirmation.

This case report describes a rare presentation of primary MCL causing life-threatening laryngotracheal stenosis, highlighting the need to consider lymphoma in the differential diagnosis of acute airway obstruction.

This case report links MCL with Henoch-Schönlein purpura and IgA-nephritis, highlighting a rare paraneoplastic syndrome with specific dermatological and renal manifestations for clinicians to recognize.

In young, newly diagnosed MCL, first-line rituximab, bendamustine, and cytarabine (R-BAP) plus a BTK inhibitor improved complete response and PFS over standard R-CHOP/R-DHAP in a real-world setting.

This systematic analysis of MAIT cells across hematological malignancies provides foundational insights into the MCL immune microenvironment, potentially identifying novel biomarkers or immunotherapy targets.

This report describes two contrasting presentations of MCL with plasmacytic differentiation, highlighting the diagnostic challenge of this rare variant which can mimic plasma cell neoplasms, impacting management.

In young, newly diagnosed MCL patients, adding ibrutinib to chemoimmunotherapy improves failure-free survival, establishing a new standard and questioning the necessity of autologous stem cell transplant consolidation.

The phase 3 TRIANGLE trial established that adding ibrutinib to induction/maintenance allows omission of autologous transplant in young, fit MCL patients, providing a new frontline, transplant-free standard.